Cancer diagnostic specialist Exact Sciences (NASDAQ: EXAS) has lagged the market over the past three years. The pandemic and the economic troubles that followed disrupted the company's operations, and the healthcare leader remains unprofitable. However, one famous name on Wall Street continues to have ...
motleyfoolusx:exas
Even companies with solid prospects sometimes fail to keep pace with the market. When that happens, it's fair to give them a closer look. In some cases, an investment could pay off handsomely in the long run, provided the companies in question have excellent prospects. Can investors find promising stocks ...
motleyfoolusx:squsx:exas
